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Multiple sclerosis (MS) is an inﬂammatory demyelinating and neurodegenerative disease initiated by autoreactive T cells.
Mgat5, a gene in the Asn (N-) linked protein glycosylation pathway, associates with MS severity and negatively regulates
experimental autoimmune encephalomyelitis (EAE) and spontaneous inﬂammatory demyelination in mice. N-glycan branching
by Mgat5 regulates interaction of surface glycoproteins with galectins, forming a molecular lattice that diﬀerentially controls the
concentration of surface glycoproteins. T-cell receptor signaling, T-cell proliferation, TH1d i ﬀerentiation, and CTLA-4 endocytosis
are inhibited by Mgat5 branching. Non-T cells also contribute to MS pathogenesis and express abundant Mgat5 branched N-
glycans. Here we explore whether Mgat5 deﬁciency in myelin-reactive T cells is suﬃcient to promote demyelinating disease.
Adoptive transfer of myelin-reactive Mgat5
−/− T cells into Mgat5
+/+ versus Mgat5
−/− recipients revealed more severe EAE in the
latter, suggesting that Mgat5 branching deﬁciency in recipient naive T cells and/or non-T cells contribute to disease pathogenesis.
1.Introduction
Multiple sclerosis (MS) is a complex trait disease where mul-
tiple genetic and environmental factors combine to inﬂuence
susceptibility to disease [1]. Concordance rates in monozy-
gotic twins is ∼30%, an ∼300-fold higher risk than the
general population risk of ∼0.1% [2]. However, Baranzini
et al. recently reported that they failed to observe sequence
diﬀerences in the genome, epigenome, or transcriptome of
monozygotic twins discordant for MS [3], implicating direct
environmental impact on genetic risk. The disparate preva-
lence of MS along north-south gradients implicates various
environmental factors as well, including sunshine exposure,
diet, and Vitamin D3 status [4]. Genomewide association
studies(GWAS)andcandidategeneinvestigationshaveiden-
tiﬁed a number of genes associated with MS susceptibility
[5–9] .Ar e c e n tG W A Sf o rv a r i a n t sr e g u l a t i n gM Ss e v e r i t y
identiﬁedMgat5,ageneencodinganenzymeintheAsn(N-)
linked protein glycosylation pathway [10]. Mgat5 catalyzes
the addition of β1,6-GlcNAc to N-glycan intermediates on
glycoproteins in the Golgi apparatus (Figure 1)[ 11, 12].
Indeed, we have recently shown that multiple genetic and
environmental risk factors converge to dysregulate N-glyco-
sylation in MS [13]. N-glycan branching by Mgat5a n dr e -
lated enzymes determines binding avidity of surface glyco-
proteins for galectins, interactions that form a molecular
lattice at the cell surface [14]. The galectin-glycoprotein lat-
tice regulates cell growth and diﬀerentiation by altering the
concentration of surface glycoproteins [15]. Mice deﬁcient
in Mgat5 display enhanced delayed-type hypersensitivity,
spontaneous kidney autoimmunity, and increased suscepti-
bility to experimental autoimmune encephalomyelitis (EAE)
[16]. Furthermore, mouse strains susceptible to EAE (PL/J,
SJL,andNOD)displayreducedN-glycanbranchinginTcells
compared with strains resistant to EAE (129/Sv, BALB/c, and
B10.S) [17]. The PL/J strain displays the lowest levels of N-
glycan branching with mass spectroscopy and enzyme assays
demonstratingdeﬁcienciesinmultipleN-glycosylationpath-
way enzymes. A small minority of aged PL/J mice develop2 ISRN Neurology
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Figure 1: GlcNAc-branched N-glycan biosynthesis. UDP-GlcNAc is required by the N-acetylglucosaminyltransferases Mgat1, 2, 4, and 5
and iGnT. Cytosolic UDP-GlcNAc enters the Golgi via antiporter exchange with Golgi UMP, a reaction product of the N-acetylglucosamin-
yltransferases. Galectins bind N-acetyllactosamine, with avidity increasing in proportion to the number of N-acetyllactosamine units (i.e.,
branching). β-1,6-GlcNAc-branching by Mgat5 promotes poly-N-acetyllactosamine production, further enhancing avidity for galectins.
GalT3, galactosyltransferase 3.
a spontaneous late-onset clinical disease manifested by
inﬂammatory demyelination and neurodegeneration, phe-
notypes markedly enhanced by Mgat5+/− and Mgat5
−/−
genotypes in a gene dose-dependent manner. Mgat5
−/− PL/J
mice with spontaneous disease display features of chronic
MS, including slow progressive paralysis, tremor, focal dys-
tonic posturing, paroxysmal dystonia, neuronophagia, and
axonal damage in demyelinated lesions and normal white
matter [17–19]. Increasing N-glycan branching in T cells by
metabolically increasing availability of substrate (i.e., UDP-
GlcNAc) to Mgat5 in the Golgi suppresses autoimmune
pathogenesis. In vitro supplementation of encephalitogenic
T cells with the simple sugar N-acetylglucosamine (GlcNAc),
whichenhancesmetabolicsupplyofUDP-GlcNActo Mgat5,
reducedtheincidenceandseverityofEAEfollowingadoptive
transfer of the cells into na¨ ıve recipient mice [20]. Oral
GlcNAc also reduced the development of spontaneous dia-
betes in nonobese diabetic mice [20].ISRN Neurology 3
InTcells,Mgat5branchingandthegalectinlatticeinhib-
it basal and activation signaling, through the T-cell receptor
(TCR) and CD45 in resting cells, promote growth arrest
by cytotoxic T-lymphocyte antigen-4 (CTLA-4) in blasting
cells and enhance TH2o v e rT H1/ TH17 diﬀerentiation [15,
16, 21–26]. These T-cell-speciﬁc phenotypes are consistent
with enhanced susceptibility to demyelinating disease in
Mgat5-deﬁcient mice; however, they do not exclude disease
promotion by non-T cells. Here we investigate whether
Mgat5 branching deﬁciency in myelin-reactive T cells is
suﬃcient to promote EAE.
2.MaterialsandMethods
2.1. Experimental Autoimmune Encephalomyelitis (EAE)
Induction. Adoptive transfer EAE was induced by subcuta-
neous immunization of Mgat5
−/− PL/J mice with 100μgo f
bovine myelin basic protein (MBP) (Sigma) emulsiﬁed in
complete Freund’s adjuvant containing 4mg/mL heat-in-
activated Mycobacterium tuberculosis (H37RA; Difco) dis-
tributed over two spots on the hind ﬂank. Splenocytes were
harvested 10 days following immunization and stimulated in
vitro with 50μg/mL MBP. After 48h of incubation, CD3+
T cells were puriﬁed by negative selection (R&D Systems).
2.7 million CD3+ T cells were injected intraperitoneally into
na¨ ıve PL/J Mgat5+/+ (n = 7) and Mgat5
−/− (n = 8) mice.
Trypan blue exclusion determined <5% dead cells prior to
injection. Mice were weighed and examined daily for clinical
signs of EAE over the next 40 days with the observer blinded
to experimental conditions. Mice were scored daily in a
blinded fashion as follows: 0, no disease; 1, loss of tail tone;
2, hindlimb weakness; 3, hindlimb paralysis; 4, forelimb
weaknessorparalysisandhindlimbparalysis;5,moribundor
dead. All procedures and protocols with mice were approved
by the Institutional Animal Care and Use Committee of the
University of California, Irvine, Calif, USA.
2.2. Cytokine Measurement. Supernatant from splenocyte
cultures simulated with 50μg/mL bovine MBP (Sigma) for
48 hours were tested for IFN-γ and TNF-α levels by a mul-
tiplexing immunoassay, a bead-based analyte detection sys-
tem using ﬂow cytometry (FlowCytomix; eBioscience).
2.3. Statistical Analysis. Statistical analysis and P values for
EAE disease incidence was determined by Fisher’s exact test.
P values for EAE mean clinical score, disease duration, and
the highest clinical score were determined by the Mann-
Whitney test.
3. Results
To further investigate the eﬀects of N-glycan processing deﬁ-
ciencyin T-cell-dependentautoimmunityinvivo, weutilized
anadoptivetransfermodelofEAEinduction.Speciﬁcally,we
wanted to examine whether N-glycan branching deﬁciency
in self-reactive T cells is suﬃcient to enhance autoimmune
demyelination. EAE may be induced by adoptive transfer
of myelin antigen-speciﬁc T cells into na¨ ıve mice, leading
to inﬂammatory demyelination of axons and progressive
motor weakness. Splenocytes from myelin basic protein-
(MBP-) immunized Mgat5
−/− PL/J mice were restimulated
in vitro with MBP, then puriﬁed T cells were transferred
into Mgat5+/+ or Mgat5
−/− PL/J mice for induction of EAE.
Although the same myelin-reactive T cells were injected,
the recipient mice deﬁcient in Mgat5 displayed dramatically
increasedincidenceandseverityofEAEcomparedwithwild-
type mice (Figures 2(a) and 2(b)). At the peak of disease, less
than 15% of the wild-type mice had disease, whereas greater
than60%oftheMgat5
−/− micedisplayedEAE(Figure 2(a)).
Furthermore, the mean highest clinical score and disease
duration were signiﬁcantly increased in the Mgat5
−/− mice
(Figures 2(c) and 2(d))( Table 1). The Mgat5
−/− mice also
appeared to have slightly greater weight loss, but this was
not signiﬁcantly diﬀerent (Figure 2(e)). Splenocyte cultures
from Mgat5
−/− mice displayed increased levels of the proin-
ﬂammatory cytokines IFN-γ and TNF-α when restimulated
with MBP compared with wild-type mice (Figure 3). These
results suggest that recipient mice lacking Mgat5-modiﬁed
glycans are more susceptible to EAE autoimmune disease
following adoptive transfer of encephalitogenic Mgat5
−/− T
cells, implicating cells of the host’s own immune or cen-
tral nervous system. This raises the possibility that Mgat5
deﬁciency in host, nonantigen-speciﬁc T cells and/or non-T
cells (i.e., B cells, antigen-presenting cells, and nonimmune
cells) contribute to increased susceptibility to inﬂammatory
demyelination.
4. Discussion and Conclusions
During CNS inﬂammation, antigen-presenting cells (APC)
such as invading macrophages and resident microglia can
perpetuate the inﬂammatory milieu by secreting inﬂamma-
tory factors and presenting myelin epitopes to autoreactive T
cells. Endogenous presentation of myelin epitopes by APCs
during acute inﬂammation can initiate epitope spreading
and augment the progression of disease [27]. The diﬀerences
in EAE observed in Mgat5+/+ versus Mgat5
−/− mice follow-
ing adoptive transfer of Mgat5
−/− MBP-reactive T cells may
result from a number of diﬀerent mechanisms. Hyperactive
endogenous T cells in Mgat5
−/− recipients may respond
more vigorously to epitope spreading, thereby enhancing
disease. Mgat5
−/− macrophages have impaired motility and
phagocytosis, which may promote inﬂammatory demyeli-
nation and epitope spreading by inhibiting migration away
from sites of demyelination and/or clearance of apoptotic
cells [28]. Others have suggested that N-glycan branching
deﬁciency in the kidney induced by Golgi α-mannosidase-II
deﬁciency may trigger kidney autoimmunity via loss of self-
recognition by the innate immune system [29], raising the
possibility that reduced branching in oligodendrocytes may
similarly activate innate immune cells. Galectin-1 has also
been shown to regulate dendritic cell function by increasing
tolerogenic signals to T cells and suppressing autoimmune
neuroinﬂammation [30].
Multiple Sclerosis is also characterized by neurodegen-
eration. Although this may be triggered by inﬂammatory4 ISRN Neurology
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Figure 2: Mice deﬁcient in Mgat5 are more susceptible to EAE. (a–e), Splenocytes were isolated from Mgat5
−/− mice 10 days after
immunizationwithMBP+completeFreund’sadjuvant(CFA)andrestimulatedinvitrowithMBPfortwodays.2.7millionCD3+ Tcellswere
injected into na¨ ıve Mgat5
+/+ or Mgat5
−/− mice and scored for clinical signs of EAE daily for 40 days. Mice were weighed daily throughout
the duration of the experiment and used to determine maximum weight ﬂuctuations. P value for EAE incidence was determined by Fisher’s
exact test. P values for EAE mean clinical score, disease duration, and the highest clinical score were determined by the Mann-Whitney
test.ISRN Neurology 5
Table 1: Clinical observations of adoptive transfer EAE.
Genotype n Mean High Score Incidence Day of Onset Mean Duration (Days)
(Mean ± SEM) (Day 20) (Day 40) (Mean ± SEM) (Mean ± SEM)
P = 0.009 P = .014
Mgat5
+/+ 70 .3 ±0.20 % 0 % 9 .5 ±1.53 . 4 ± 2.6
Mgat5
−/− 81 .5 ±0.3 63% 38% 7.3 ±1.8 20.8 ± 4.9
Mice were scored daily on a scale of 0–5 with: 0, no disease; 1: loss of tail tone; 2: hindlimb weakness; 3: hindlimb paralysis; 4: forelimb weakness or paralysis
and hindlimb paralysis; 5: moribund or dead. P values for EAE mean high score and disease duration were determined by the Mann-Whitney test.
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Figure 3: Mice deﬁcient in Mgat5 have increased IFN-γ and TNF-α levels. Splenocytes were harvested from representative mice from
both EAE groups and re-stimulated with 50ug/mL MPB in vitro. Supernatants from splenocyte cultures were tested for IFN-γ and TNF-
α levels by a bead-based analyte detection system using ﬂow cytometry. ∗P ≤ 0.05. Error bars indicate the means ± S.E. of duplicate
samples.
mediators and/or demyelination, deﬁciencies in N-glycan
branching in neurons/axons may directly contribute to neu-
rodegeneration independent from eﬀects on inﬂammatory
cells. The progressive MS-like disease that spontaneously
develops in Mgat5
−/− PL/J mice displays neuronal loss and
axonal damage in both demyelinated areas and otherwise
normal appearing white matter, the latter a hallmark of MS
[17]. Moreover, neuron-speciﬁc deletion of Mgat1, a Golgi
enzyme upstream of Mgat5 that eliminates all branching
in N-glycans, results in apoptosis of adult neurons in vivo
[31]. This conﬁrms that N-glycan branching is required for
neuronal viability in the adult CNS.
Restoration of neuronal integrity and regeneration of
myelinated axons in the damaged CNS is another important
mechanism to consider. Neural stem cells residing in the
CNS are implicated in regenerating the damaged CNS, and,
evenwithinanacuteinﬂammatorybrainlesion,spontaneous
remyelination occurs [32]. Recently, it has been shown that
galectin-1promotesproliferationofadultneuralstemcellsin
theCNSthroughitscarbohydrate-binding ability, suggesting
that N-glycan branching deﬁciency may also limit regener-
ative mechanisms in MS and thereby promote progression
[33]. Indeed, a polymorphism in Mgat5 strongly associates
with disease severity in MS [10]. Future investigations are
warranted to examine the many potential mechanisms by
which deﬁciency of N-glycan branching by Mgat5 and other
Golgi enzymes contribute to demyelinating disease initiation
and progression.
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